Sanofi (ENXTPA:SAN) - Stock Price, News & Analysis

SAN Stock Overview

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.

About the company

SAN fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	1/6
Financial Health	6/6
Dividends	5/6

Rewards

Trading at 61.6% below our estimate of its fair value

Earnings are forecast to grow 16.89% per year

Pays a reliable dividend of 4.14%

Risk Analysis

Large one-off items impacting financial results

Profit margins (9.8%) are lower than last year (18.1%)

Sanofi Competitors

Ipsen

ENXTPA:IPN

€10.0b

Virbac

ENXTPA:VIRP

€3.0b

Vetoquinol

ENXTPA:VETO

€1.2b

Boiron

ENXTPA:BOI

€600.7m

Price History & Performance

Summary of all time highs, changes and price drops for Sanofi
Historical stock prices
Current Share Price	€90.00
52 Week High	€104.32
52 Week Low	€80.60
Beta	0.44
1 Month Change	2.08%
3 Month Change	1.42%
1 Year Change	-10.79%
3 Year Change	1.51%
5 Year Change	22.85%
Change since IPO	116.35%

Recent updates

Shareholder Returns

	SAN	FR Pharmaceuticals	FR Market
7D	-0.6%	-1.7%	-0.9%
1Y	-10.8%	-9.4%	6.6%

Return vs Industry: SAN matched the French Pharmaceuticals industry which returned -9.4% over the past year.

Return vs Market: SAN underperformed the French Market which returned 6.6% over the past year.

Price Volatility

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	3.6%
Market Average Movement	4.5%
10% most volatile stocks in FR Market	9.6%
10% least volatile stocks in FR Market	2.3%

Stable Share Price: SAN has not had significant price volatility in the past 3 months.

Volatility Over Time: SAN's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	86,088	Paul Hudson	www.sanofi.com

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SAN fundamental statistics
Market cap	€112.51b
Earnings (TTM)	€4.54b
Revenue (TTM)	€46.29b

24.8x

P/E Ratio

2.4x

P/S Ratio

Is SAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SAN income statement (TTM)
Revenue	€46.29b
Cost of Revenue	€14.58b
Gross Profit	€31.71b
Other Expenses	€27.17b
Earnings	€4.54b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)	3.63
Gross Margin	68.51%
Net Profit Margin	9.80%
Debt/Equity Ratio	24.8%

How did SAN perform over the long term?

See historical performance and comparison

Dividends

4.2%

Current Dividend Yield

87%

Payout Ratio

SAN Stock Overview

Rewards

Risk Analysis

Sanofi Competitors

ENXTPA:IPN

€10.0b

ENXTPA:VIRP

€3.0b

ENXTPA:VETO

€1.2b

ENXTPA:BOI

€600.7m

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Price target decreased by 8.3% to €106

Third quarter 2023 earnings: EPS misses analyst expectations

Sanofi Reiterates Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 18%

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Shareholder Returns

Price Volatility

About the Company

Sanofi Fundamentals Summary

24.8x

2.4x

Earnings & Revenue

Dividends

4.2%

87%